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ABSTRACT
Nasopharyngeal pneumococci were collected from
635 Spanish children aged 6 months to 6 years
attending four primary healthcare centres (n = 276)
or two hospital emergency rooms (n = 359); 36% of
the children had received ‡1 dose of pneumococcal
conjugate vaccine (PCV7). Overall, the carriage rate
of Streptococcus pneumoniae was 31%, with no
significant differences in carriage rates according
to setting. Colonization with vaccine serotypes was
significantly associated with the absence of PCV7
immunization (29.4% vs. 5.9%, p <0.001). Forty-
seven per cent of all isolates were penicillin- and ⁄ or
erythromycin-non-susceptible; 13 international
antibiotic-resistant clones were represented among
non-susceptible pneumococci and were similarly
distributed among vaccine and non-vaccine
serotypes.
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The introduction of the pneumococcal conjugate
vaccine (PCV7) in the USA was followed by a
reduction in penicillin and macrolide non-suscep-
tibility rates among invasive isolates [1,2]; how-
ever, this effect on resistance may be temporary,
since antimicrobial resistance among non-vaccine
serotypes (NVTs) has increased [3,4]. A cross-
sectional nasopharyngeal (NP) carriage study was
conducted from January 2005 through June 2006
to assess the distribution of serotypes and geno-
types (clones) among penicillin-non-susceptible
pneumococci (PNSP) and erythromycin-non-sus-
ceptible pneumococci (ENSP), when vaccine
uptake was low to medium. Only limited infor-
mation on the molecular epidemiology of NP
carriage after PCV7 introduction exists, and it
derives from areas of the USA with high vaccine
coverage [5].
NP swab specimens were obtained from 635
children aged 6 months to 6 years attending four
primary healthcare centres (PHCs) and two hos-
pital emergency rooms (ERs) in Seville. Two
hundred and seventy-six (43%) children were
seen during a well-child visit to the PHCs, and the
remaining 359 (57%) were sick children seeking
medical attention in the ER. The age distributions
in both populations were similar (median age
2 years, interquartile range 1–3 years). All chil-
dren who attended the participating centres
during less congested periods of the day, i.e. with
the personnel under less pressure, were recruited.
Exclusion criteria were: chronic medical condi-
tion, moderate-to-severe acute process including
fever >39C, vomiting, dehydration and lower
respiratory tract infection. Written informed con-
sent was obtained from the parent or legal
guardian of participating children prior to NP
swabbing. The percentages of children who had
received antimicrobial treatment during the pre-
ceding 2 months and ‡1 dose of PCV7 were 28%
and 36%, respectively.
The study was conducted according to WHO
recommendations [6]. Serotyping by the Quellung
reaction and ⁄ or dot blot assay [7] and antimicro-
bial susceptibility testing by the agar dilution
technique [8] were performed by the Spanish
Reference Laboratory. MIC interpretative break-
points for penicillin and erythromycin non-sus-
ceptibility were ‡0.12 mg ⁄mL and ‡0.5 mg ⁄mL,
respectively. Macrolide resistance genes were
detected by PCR [9]. Multilocus sequence typing
Corresponding author and reprint requests: I. Obando, Lon-
dres 98, 41012 Sevilla, Spain
E-mail: iosantaella@telefonica.net
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases
of all isolates was performed [10]. Analysis of
categorical variables was performed using the v2
test and Fisher’s exact test, as appropriate.
Overall, the carriage rate of Streptococcus pneu-
moniae was 31% (194 ⁄ 635), with no significant
differences in carriage rates according to setting
(33% in ER vs. 28% in PHC, p = 0.15). PCV7
serotypes (vaccine serotypes (VTs)) accounted for
23% (44 ⁄ 194) of NP isolates. Colonization with
VTs was significantly associated with lack of
PCV7 immunization (29.4% vs. 5.9%, p < 0.001).
Thirty-three different serotypes were identified;
6A (12%), 14 (8%), 19A (7%), non-typeable (6%)
and 11 (6%) were the most frequently detected.
Ninety-one (47%) of the 194 NP isolates were
penicillin-non-susceptible and ⁄ or erythromycin-
non-susceptible. Thirty-one per cent (28%
intermediate and 3% high-level resistant) were
penicillin-non-susceptible and 37% were erythro-
mycin-non-susceptible. Among 72 erythromycin-
non-susceptible strains, 57 (79%) possessed the
erm(B) gene, 11 (15%) possessed the mef(A)
family gene, and four (6%) possessed both genes.
The penicillin-non-susceptible and erythromycin-
non-susceptible percentages were significantly
higher among VTs than among NVTs (68% vs.
21%; p < 0.001 and 52% vs. 33%; p 0.001, respec-
tively).
Seventy-four sequence types (STs) were identi-
fied among all isolates. Thirty-one STs (42%) were
associated with PNSP and ⁄ or ENSP (Tables 1 and
2); 73% of these STs were identical or related
(single-locus variant and double-locus variant) to
13 of 43 Pneumococcal Molecular International
Network (PMEN) international clones (http://
www.sph.emory.edu/PMEN). The proportions of
PMEN and related clones among strains associ-
ated with PNSP and ⁄ or ENSP were similarly
distributed among VTs and NVTs (12 ⁄ 14 vs.
14 ⁄ 20, p 0.42).
Thirteen strains were ST338 (Colombia23F-26),
eight of which were serotype 6A, which repre-
sents a possible capsular switch event not previ-
ously reported. The serotype 14 variant of ST156
(Spain9V-3) was the next most frequently identi-
fied genotype (n = 12); eight of these were peni-
cillin-susceptible and only four of
them were penicillin-susceptible and erythromy-
cin-non-susceptible. Among NVTs, strains of
serotypes 33 and 35B were clonal (one ST of
each was detected); serotype 33 was erythromy-
cin-non-susceptible but penicillin-susceptible,
whereas serotype 35B was erythromycin-non-sus-
ceptible and penicillin-susceptible. In contrast,
strains of serotypes 6A and 19A were genetically
diverse.
The observed carriage rate is comparable to
those reported in two Spanish NP carriage studies
performed during the pre-vaccine years in differ-
ent settings [11,12]. Serotype distribution was
available for only one study, but these data are
difficult to compare with the study data because
Table 1. Clonal analysis of pneumococcal nasopharyngeal (NP) isolates belonging to vaccine serotypes (VTs) associated
with penicillin and ⁄ or erythromycin non-susceptibility (n = 41)a
Serotype
No. of isolates
(% of 194 NP isolates)a
STs (n) among pneumococci that are non-susceptible to:
PMEN and related clonesPenicillin + erythromycin Penicillin only Erythromycin only Neither
6B 8 (4) ST90 (2) Spain6B-2
ST94 (2) SLV Spain6B-2
ST2156 (1) SLV Spain6B-2
ST2199 (1) DLV Spain6B-2
ST386 (1) DLV Poland6B-20
ST315 (1) Poland6B-20
9V 3 (2) ST838 (3) SLV Spain9V-3
14 14 (7) ST156 (4) ST156 (8) Spain 9V-3
ST409 (1)
ST2607 (1)
19F 8 (4) ST81 (3) Spain23F-1
ST63 (1) Sweden15A-25
ST87(1)
ST179 (2) SLV Portugal19F-21
ST2615 (1)
23F 8 (4) ST81 (2) ST81 (1) Spain23F-1
ST338 (2) ST338 (2) Colombia23F-26
ST1852 (1)
Total no. 41 17 13 6 5
ST, sequence type; PMEN, Pneumococcal Molecular Epidemiology Network; SLV, single-locus variant; DLV, double-locus variant.
aOne hundred and ninety-four NP pneumococci were collected in total. Only VT pneumococci with an association with penicillin and ⁄ or erythromycin non-susceptibility are
included here—fully susceptible VT pneumococci are not shown.
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samples were obtained from older children and
44.5% of the strains were non-typeable [11]. The
penicillin resistance rate found in this carriage
study was lower than rates reported in the pre-
vaccine carriage studies and also in the Spanish
surveillance of paediatric invasive and respiratory
pneumococcal isolates [11–14]. This finding coin-
cides with the significant decrease in penicillin
non-susceptibility observed in Spain in recent
years, probably due to PCV7 introduction and a
reduction in antibiotic consumption [15,16].
Antibiotic-non-susceptible NVTs in this study
were generally restricted to serotypes associated
with penicillin non-susceptibility during the
pre-vaccine years in Spain [17] which have rarely
caused invasive disease in recent years in the
geographical area of the study, except for sero-
type 19A. In this regard, the impact of PCV7 on
the epidemiology of invasive pneumococcal dis-
ease in different areas of Spain has been evalu-
ated, with conflicting results [18,19]. However,
interpretation of changes in incidence of invasive
pneumococcal disease and serotype distribution
is confounded by the fact that vaccine uptake has
been gradual, with limited coverage until very
recently, and by the fact that there has been
a marked increase in the prevalence of highly
invasive serotype 1, related partly to the
Table 2. Clonal analysis of pneumococcal nasopharyngeal (NP) isolates belonging to non-vaccine serotypes that are
associated with penicillin and ⁄ or erythromycin non-susceptibility (n = 104)a
Serotype
No. of isolates
(% of 194 NP isolates)a
STs (n) among pneumococci that are non-susceptible to:
PMEN and related clonesPenicillin + erythromycin Penicillin only Erythromycin only Neither
6A 24 (12) ST386 (2) ST386 (3) DLV Poland6B-20
ST473 (1)
ST338 (4) ST338 (5) Colombia23F-26
ST392 (1)
ST1876 (3)
ST224 (2)
ST327 (1) Portugal6A-41
ST2201 (1)
ST2611 (1)
11 11 (6) ST2612 (1) SLV Colombia23F-26
ST62 (4) ST62 (4)
ST2614 (1) SLV Netherlands15B-37
ST2202 (1)
15A 4 (2) ST63 (2) Sweden15A-25
ST2613 (1) DLV Sweden15A-25
ST2176 (1) SLV Greece21-30
15B ⁄C 9 (5) ST193 (1) Greece21-30
ST199 (5) Netherlands15B-37
ST411 (1)
ST1262 (1)
ST2264 (1)
19A 14 (7) ST276 (2) SLV Denmark14-32
ST2609 (1) SLV Netherlands15B-37
ST199 (2) Netherlands15B-37
ST2109 (1) DLV Netherlands15B-37
ST202 (3) DLV Taiwan19F-14
ST433 (2)
ST392 (2)
ST1201 (1)
23A 9 (5) ST42 (4) ST42 (4) DLV Tennessee23F-4
ST438 (1)
24 5 (3) ST230 (3) Denmark14-32
ST72 (1)
ST97 (1)
33 5 (3) ST717 (5)
35B 6 (3) ST558 (6) SLV Utah35B-24
35F 5 (3) ST2610 (1)
ST2198 (3)
ST2203 (1)
NT 12 (6) ST344 (6) NorwayNT-42
ST942 (1)
ST941 (3)
ST100 (1)
ST448 (1)
Total no. 104 25 6 24 49
ST, sequence type; PMEN, Pneumococcal Molecular Epidemiology Network; SLV, single-locus variant; DLV, double-locus variant.
aOne hundred and ninety-four NP pneumococci were collected in total. Only non-vaccine serotype (NVT) pneumococci with an association with penicillin and ⁄ or
erythromycin non-susceptibility are included here—fully susceptible NVT pneumococci are not shown.
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introduction of ST306 [19,20] (I. Obando, unpub-
lished data). Interestingly, STs associated with
NVT pneumococci in this Spanish collection, e.g.
ST558 and ST63, expanded significantly among
colonized children in Massachusetts between
2001 and 2004 and contributed markedly to the
increased prevalence of penicillin resistance
among replacing NVT pneumococci [5]. It re-
mains to be seen whether the frequency of NVT
clones will change as vaccine coverage increases
in Spain and whether such changes will have any
subsequent effect on antibiotic resistance rates.
In conclusion, PMEN and genetically related
clones associated with antibiotic-non-susceptible
pneumococci were broadly represented in NP
carriage, both among VTs and NVTs. This is of
concern because of their ability to disseminate
widely. Continued surveillance, in conjunction
with molecular epidemiological analyses, is
needed to determine the full impact of PCV7 on
carriage and antibiotic non-susceptibility in the
Spanish population.
ACKNOWLEDGEMENTS
We thank M. A. Ferna´ndez Fernandez, A. B. R.amirez, R.
Torronteras, M. J. Gil Dominguez and I. Mateos for their
collaboration and technical assistance.
TRANSPARENCY DECLARATION
This work was supported by grant PI05 ⁄ 0924 from Fondo
de Investigaciones Sanitarias, Fundacio´n Cajasol and by
GlaxoSmithKline Biologicals. W. P. Hausdorff is an
employee of GlaxoSmithKline Biologicals. A. B. Bruegge-
mann has received grant and travel funding from Glaxo-
SmithKline Biologicals and Wyeth Vaccines, and has been an
advisor to both companies. I. Obando has received travel
funding from GlaxoSmithKline Biologicals and has been an
advisor to both GlaxoSmithKline Biologicals and Wyeth
Vaccines. The other authors have no conflict of interest.
REFERENCES
1. Kyaw MH, Lynfield R, Schaffner W et al. Effect of intro-
duction of the pneumococcal conjugate vaccine on drug-
resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:
1455–1463.
2. Stephens DS, Zughaier SM, Whitney CG et al. Incidence of
macrolide resistance in Streptococcus pneumoniae after
introduction of the pneumococcal conjugate vaccine:
population-based assessment. Lancet 2005; 365: 855–863.
3. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann
D, Finkelstein JA. Post-PCV7 changes in colonizing
pneumococcal serotypes in 16 Massachusetts communi-
ties, 2001 and 2004. Pediatrics 2005; 116: e408–e413.
4. Temime L, Guillemot D, Boelle PY. Short- and long-term
effects of pneumococcal conjugate vaccination of children
on penicillin resistance. Antimicrob Agents Chemother 2004;
48: 2206–2213.
5. Hanage WP, Huang SS, Lipsitch M et al. Post-PCV7
changes in antibiotic resistance among nonvaccine pneu-
mococcal strains in 16 Massachusetts communities. J Infect
Dis 2007; 195: 347–352.
6. O’Brien KL, Nohynek H, the WHO pneumococcal vaccine
trials carriage working group. Report from a WHO
working group: standard method for detecting upper
respiratory carriage of Streptococcus pneumoniae. Pediatr
Infect Dis J 2003; 22: e1–e11.
7. Fenoll A, Jado I, Vicioso D, Casal J. Dot blot assay for
the serotyping of pneumococci. J Clin Microbiol 1997; 35:
764–766.
8. Clinical and Laboratory Standards Institute. Methods for
dilution antimicrobial susceptibility test for bacteria that growth
aerobically, 7th 371 edn. Approved standard M7-A6. Wayne,
PA: Clinical and Laboratory Standards Institute, 2003.
9. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detec-
tion of erythromycin-resistant determinants by PCR. An-
timicrob Agents Chemother 1996; 40: 2562–2566.
10. Enright MC, Spratt BG. A multilocus sequence typing
scheme for Streptococcus pneumoniae: identification of
clones associated with serious invasive disease. Microbiol-
ogy 1998; 144: 3049–3060.
11. Garcia-de-Lomas J, Gimeno C, Millas C et al. Antimicro-
bial susceptibility of Streptococcus pneumoniae isolated from
pediatric carriers in Spain. Eur J Clin Microbiol Infect Dis
1997; 16: 11–13.
12. Lopez B, Cima MD, Vazquez F et al. Epidemiological
study of Streptococcus pneumoniae carriers in healthy pri-
mary-school children. Eur J Clin Microbiol Infect Dis 1999;
18: 771–776.
13. Pallares R, Fenoll A, Lin˜ares J. The epidemiology of
antibiotic resistance in Streptococcus pneumoniae and the
clinical relevance of resistance to cephalosporins, mac-
rolides and quinolones. Int J Antimicrob Agents 2003; 22
(suppl): 15–24.
14. Pe´rez-Trallero E, Garcı´a de la Fuente C, Garcı´a-Rey C et al.
Geographical and ecological analysis of resistance, core-
sistance and coupled resistance to antimicrobials in
respiratory pathogenic bacteria in Spain. Antimicrob Agents
Chemother 2005; 49: 1965–1972.
15. European Antimicrobial Resistance Surveillance Sys-
tem. Annual report 2005. October 2006, posting date.
Chapter 4.2.2, Streptococcus pneumoniae resistance trends:
1999–2005. http://www.rivm.nl/earss/Images/EARSS%
202005_tcm61-34899.pdf.
16. Oteo J, La´zaro E, De Abajo FJ, Baquero F, Campos J,
Spanish members of the European Antimicrobial Resis-
tance Surveillance System. Trends in antimicrobial resis-
tance in 1968 invasive Streptococcus pneumoniae strains
isolated in Spanish hospitals (2001–2003): decreasing
penicillin resistance in children’s isolates. J Clin Microbiol
2004; 42: 5571–5577.
17. Fenoll A, Asensio G, Jado I et al. Antimicrobial suscepti-
bility and pneumococcal serotypes. J Antimicrob Chemother
2002; 50 (suppl 2): 13–19.
18. Benito-Ferna´ndez J, Raso SM, Pocheville-Gurutzeta I,
Sa´nchezEtxaniz J, Azcunaga-Santiban˜ez B, Capape´-Zache
S. Pneumococcal bacteremia among infants with fever
800 Clinical Microbiology and Infection, Volume 14 Number 8, August 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 797–812
without known source before and after introduction of
pneumococcal conjugate vaccine in the Basque Country of
Spain. Pediatr Infect Dis J 2007; 26: 667–671.
19. Mun˜oz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-
Garcia JJ, Pallares R. Emergence of invasive pneumococcal
disease caused by nonvaccine serotypes in the era of 7-
valent conjugate vaccine. Clin Infect Dis 2008; 46: 174–182.
20. Obando I, Arroyo LA, Sa´nchez-Tatay D et al. Molecular
epidemiology of paediatric invasive pneumococcal disease
in southern Spain after the introduction of heptavalent
pneumococcal conjugate vaccine. Clin Microbiol Infect 2007;
13: 347–348.
RESEARCH NOTE
Activity of moxifloxacin against the
urogenital mycoplasmas Ureaplasma spp.,
Mycoplasma hominis and Mycoplasma
genitalium and Chlamydia trachomatis
C. M. Be´be´ar, B. de Barbeyrac, S. Pereyre,
H. Renaudin, M. Clerc and C. Be´be´ar
Laboratoire de Bacte´riologie EA 3671, Universite´
Victor Segalen Bordeaux 2 and CHU de
Bordeaux, Bordeaux, France
ABSTRACT
The activity of moxifloxacin was compared with
that of other antimicrobial agents against 54
strains of Ureaplasma spp., 54 strains of Myco-
plasma hominis, 14 strains of Mycoplasma genitali-
um, and 44 strains of Chlamydia trachomatis.
Moxifloxacin inhibited 90% of all isolates at a
concentration £1 mg ⁄L, being the most active
compound against C. trachomatis and sharing the
highest activity with garenoxacin and gemifloxa-
cin against mycoplasmas. Moxifloxacin killed the
30 mycoplasma isolates tested at a concentration
£1 mg ⁄L, except those resistant to fluoroquino-
lone. Thus, moxifloxacin has attracted interest as a
potential therapy for mycoplasmal or chlamydial
urogenital infections.
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The urogenital mycoplasmas Mycoplasma hominis,
M. genitalium and Ureaplasma spp., and Chlamydia
trachomatis, are involved in genitourinary
infections in men and women. The antibiotics
potentially active against mycoplasmas and
C. trachomatis are relatively low in number, and
include tetracyclines, macrolides and related anti-
biotics, and fluoroquinolones. Among fluoroqui-
nolones, the newer products, e.g. moxifloxacin,
have the highest in vitro activity against these
microorganisms. The activity of moxifloxacin
against human mycoplasmas [1–4] and C. tracho-
matis [5–7] has already been studied. These studies
concerned a relatively low number of isolates and
evaluated its bactericidal activity against myco-
plasmas for only three Ureaplasma spp. and two
M. hominis strains [4]. Our purpose was to extend
the study of the in vitro activity of moxifloxacin to a
larger number of strains of urogenital mycoplas-
mas, including M. genitalium and C. trachomatis,
in comparison with other fluoroquinolones—
ofloxacin against C. trachomatis; ofloxacin, and
levofloxacin, gatifloxacin, gemifloxacin and gare-
noxacin against mycoplasmas—and with other
antimicrobials, including erythromycin, azithro-
mycin and doxycycline. Moreover, the MBCs of
moxifloxacin for nine strains of Ureaplasma spp.,
seven strains of M. hominis and 14 strains of
M. genitalium were determined.
Fifty-four strains of Ureaplasma spp., one Urea-
plasma parvum and one U. urealyticum reference
strain, 30 doxycycline-susceptible clinical isolates
collected prospectively between 2003 and 2005,
and 22 doxycycline-resistant clinical isolates
collected prospectively between 1996 and 2005
at Pellegrin Hospital, Bordeaux, France, were
studied. For M. hominis, 54 strains were evaluated,
two reference strains, 32 doxycycline-susceptible
clinical isolates collected prospectively between
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